Large study monitors kidney disease drug in Real-World use
NCT ID NCT02847624
Summary
This study monitored the safety and effectiveness of the drug tolvaptan in over 1,800 patients with ADPKD in Japan after it was approved for use. The main goal was to see how well the drug slowed the growth of kidney cysts in everyday medical practice and to track any side effects, especially related to liver health. It was an observational study, meaning researchers collected data from patients already prescribed the medication by their doctors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.